Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP1 inhibits cisplatin. 2 / 2

| 2

➶

reach

"This view has gained recent support with the finding that USP1 inhibition may contribute to revert cisplatin resistance in an in vitro model of non small cell lung cancer (NSCLC)."

23937906

➶

reach

"These findings are consistent with those of Chen et al. [XREF_BIBR], and suggest that USP1 inhibition may contribute to revert cisplatin resistance in some preclinical models of NSCLC."

23937906

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...